Source-grounded facts extracted from Passage BIO, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Passage BIO, Inc. announced a restructuring with charges of approximately $3.3 million (approximately 75%).
“The Company expects that the aggregate severance and exit costs for the Restructuring Plan will be approximately $3.3 million, which will be recorded primarily in the second quarter of 2026.”
Passage BIO, Inc. terminated Hopewell Lease Termination Agreement with Hopewell Campus Owner LLC valued at termination fee of approximately $4.8 million plus accrued rent through February 14, 2026 (effective 2026-03-04).
“On March 4, 2026, Passage Bio, Inc. (the "Company") and Hopewell Campus Owner LLC (the "Landlord") entered into a lease termination agreement (the "Termination Agreement") with respect to that certain lease agreement dated December 15, 2020 between the Company and Landlord (the "Hopewell Lease").”
Passage BIO, Inc.: 1-for-20 reverse stock split effective July 14, 2025 (effective 2025-07-14).
“On July 11, 2025, Passage Bio, Inc. (the “ Company ”) filed a Certificate of Amendment (the “ Amendment ”) to its Amended and Restated Certificate of Incorporation (the “ Certificate of Incorporation ”) with the Secretary of State of the State of Delaware to implement a 1-for-20 reverse stock split (the “ Reverse Stock Split ”) of the Company’s common stock, par value $0.0001 per share (the “ Common Stock ”) to be effective as of 12:01 am Eastern time on July 14, 2025 (the “ Effective Time ”).”
Passage BIO, Inc. received a nasdaq extension granted notice regarding minimum bid price.
“January 29, 2025, the Nasdaq Listing Qualifications department approved the Company’s request to transfer the listing of the Company’s shares of common stock from The Nasdaq Global Select Market to The Nasdaq Capital Mar”
Thomas Kassberg was appointed as Class I director at Passage BIO, Inc..
“On September 9, 2024, the board of directors (the “ Board ”) of Passage Bio, Inc. (the “ Company ”), upon the recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Thomas Kassberg as a Class I director and as a member of the Audit Committee of the Board, effective as of September 10, 2024 (the “ Appointment Date ”).”
Mark Forman resigned as Chief Medical Officer at Passage BIO, Inc..
“On July 26, 2024, Mark Forman, M.D., Ph.D., notified the Company of his decision to resign from his position as the Company’s Chief Medical Officer, effective as of August 2, 2024.”
Passage BIO, Inc. reported first quarter ended March 31, 2024 results: net income Net loss was $16.7 million, or $0.30 per basic and diluted share.
“Passage Bio, Inc. (Nasdaq: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today reported financial results for the first quarter ended March 31, 2024”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.